According to a new report by Polaris Market Research, the global multiomics market was valued at USD 3.20 billion in 2025 and is projected to reach USD 11.53 billion by 2034, expanding at a CAGR of 15.30% from 2026 to 2034. Growth is underpinned by rising adoption of single-cell and spatial profiling, expanding research funding, and accelerating integration of artificial intelligence across genomics, transcriptomics, proteomics, and metabolomics workflows.

What Is Driving Multiomics Market Growth?

Demand is climbing as technological advancement in single-cell and spatial platforms converges with rising research funding and pharmaceutical R&D investment. Instrument makers and research institutions are prioritizing AI-assisted data integration, pushing multiomics adoption across biotechnology, pharmaceutical, and academic research settings. Polaris analysts note that the growing burden of chronic disease worldwide positions the single-cell segment for sustained double-digit growth through 2034, with the product & services category emerging as the largest revenue contributor and the metabolomics platform posting the fastest incremental gains.

Key Trends Shaping the Multiomics Industry

AI-Enabled Multiomics Data Integration

Artificial intelligence is being layered onto multiomics workflows to process large, heterogeneous datasets faster, identify biomarkers and disease patterns, and shorten the timeline from data generation to actionable research insight. This technology advancement is reducing manual interpretation time while improving reproducibility across genomics, proteomics, and metabolomics layers.

Government and Institutional Support for Genomics Research

Public funding programs are expanding the pool of multiomics data available to researchers. National-level initiatives are adding proteomics and RNA sequencing data at scale, broadening the regulatory landscape supportive of precision-health research and reinforcing long-term market outlook.

Strategic Partnerships and Platform Consolidation

Instrument and software vendors are pursuing partnerships and bolt-on acquisitions to build integrated multiomics ecosystems rather than standalone single-layer tools, reflecting a broader competitive landscape shift toward platform-based offerings that combine sequencing, spatial biology, and cloud analytics.

Market Segmentation: Breaking Down the Multiomics Market

Polaris segments the multiomics market by product & service, type, platform, application, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product & Service

The product & service category led the market in 2025, accounting for 76.0% of revenue on the strength of strong demand for instruments, consumables, and multiomics-ready software. Within this category, instruments represent the largest share at 42%, while services account for roughly a quarter of segment revenue as more labs outsource complex multiomics workflows.

Read More @ https://www.polarismarketresearch.com/industry-analysis/multiomics-market

By Type

The single-cell multi-omics segment led the market in 2025, accounting for 52.0% of revenue on the strength of expanding use in cancer research, gene therapy, and single-cell studies. The bulk multi-omics segment is projected to expand at a notable CAGR of 12.30% through 2034 as cost efficiency and simplicity continue to support large-scale sample analysis.

By Platform

Genomics remains the dominant platform, capturing the largest share of 32.0% in 2025 on declining sequencing costs and continued advances in data-analysis tools. The metabolomics platform is projected to expand at the fastest CAGR of 14.8% through 2034 as it becomes more central to personalized-medicine and drug-discovery pipelines.

By Application

Oncology remains the dominant application area given the ongoing need for biomarker discovery and precision cancer treatment, while neurology and immunology are emerging as pharmaceutical companies and research institutions increasingly use multiomics to unpack complex disease mechanisms and identify new therapeutic targets.

Regional Outlook: Where Is Multiomics Growing Fastest?

North America led the market in 2025, holding 38.0% of global revenue on the back of a dense concentration of key players, strong research-industry collaboration, and rising chronic-disease burden across the region. Europe is expected to post the fastest CAGR of 14.9% through 2034, driven by government-backed genomics initiatives such as France's national genomic medicine plan. Within North America, the U.S. remains the largest single market; within Europe, growth is broadly distributed across the UK, Germany, and France. Asia Pacific rounds out the leading growth regions, supported by expanding genomics investment in China, Japan, and India.

Competitive Landscape: Leading Multiomics Companies

Key players are focusing on partnerships, platform launches, and acquisitions to strengthen market position across the single-cell multi-omics and oncology application segments outlined above. Recent moves include Illumina's launch of its StrataMap spatial transcriptomics solution and its Illumina Connected Multiomics cloud platform, alongside Bruker's acquisition of metabolomics specialist Biocrates, both aimed at deepening capability in North America and Europe.

Key players profiled include BD, Thermo Fisher Scientific, Inc., Illumina, Inc., Beckman Coulter Life Sciences, Revvity, Inc., Shimadzu Corporation, Bruker, QIAGEN N.V., Agilent Technologies, Inc., BGI Genomics Co., Ltd., 10x Genomics, Inc., Bio-Rad Laboratories, Inc., Mission Bio, Inc., Standard BioTools Inc., Takara Bio Inc..

Why It Matters for Buyers Evaluating Precision-Medicine Market Entry

For stakeholders researching the multiomics market opportunity, this report benchmarks market share, segment-level pricing, and forecast data — by product & service, type, platform, application, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking metabolomics as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

market-research-vs-marketing-research

top-10-herbal-supplement-companies-in-the-global-market-2025

dairy-foods-market

top-5-companies-in-skateboard-market-to-know-in-2025

tacrolimus-market

purified-terephthalic-acid-market

risk-management-market

alpha-gal-syndrome-allergy-market

ai-in-oncology-market